A prospective randomised trial comparing the modified HM3 with the MODULITH® SLX-F2 lithotripter

Pascal Zehnder1, Beat Roth, Frédéric Birkhäuser

  • 1Department of Urology, University of Bern, Bern, Switzerland.

European Urology
|February 8, 2011
PubMed
Summary

The modified HM3 lithotripter demonstrated superior effectiveness in extracorporeal shock wave lithotripsy (ESWL), requiring fewer shock waves and leading to better stone-free rates for certain stone types compared to the MODULITH SLX-F2. This advanced lithotripter also resulted in fewer complications and secondary treatments.

Related Concept Videos